Dolabellane diterpenoids as non-nucleoside reverse transcriptase inhibitors and anti- HIV agents: in silico and biological approach.

Authors

Ashwini Kolukula, Tejasvini Kamdar, Swapnanjali Karamtoth, Sai Satya Sri Pulla, Katragadda Suresh Babu, Nishant Jain, Surender Singh Jadav, Vedula Girija Sastry

Published in

Natural product research. Pages 1-8. Jul 17, 2026. Epub Jul 17, 2026.

Abstract

Human Immunodeficiency Virus (HIV) impacts the immune system and is rapidly evolving with a high number of newly infected cases leading to mortality. However, there is an unmet medical need to identify novel anti-HIV. To identify novel anti-HIV agents, marine products can be considered as a vital source. Previously, we reported cytotoxic activity of 13 compounds belonging to the dolabellane diterpenes scaffold. Here, we tested if our panel of dolabellane diterpene scaffolds also inhibits HIV using in vitro and in vivo assays. We found that dichodictyol E (5), dichodictyol H (8) and 12 inhibit HIV RT enzyme in vitro and infection in vivo. Molecular docking analysis reveals that dichodictyol E (5), dichodictyol H (8) and 12 bind to HIV 1 reverse transcriptase enzyme. We conclude that Dolabellane diterpenoids act as reverse transcriptase inhibitors and anti-HIV agents and are amenable to further structural modifications to make potent anti-HIV agents.

PMID:
42467899
Bibliographic data and abstract were imported from PubMed on 18 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.